Covid-19: Swiss nasal spray vaccine to enter clinical trials

(MENAFN- Swissinfo) As a nasal spray the vaccine would be easier to administer, transport and store. Keystone / Ennio Leanza

A Swiss-led research consortium has partnered with Basel-based biotech company RocketVax to launch clinical trials for two second-generation Covid-19 vaccine candidates. This includes a nasal spray vaccine.

This content was published on March 17, 2022 - 11:19 March 17, 2022 - 11:19 Keystone-SDA/jdp

• Español (es) COVID-19: Vacuna suiza en aerosol nasal entrará en fase de ensayo
• Português (pt) Vacina suíça de spray nasal entra em fase de testes

The research consortium, led by virologist Volker Thiel at the University of Bern, announced on Wednesday that it had signed a partnership with RocketVax to start clinical trials for new vaccine candidates. These are live-attenuated vaccines, which use a form of the virus that doesn't make people ill but elicits an immune response. Such live vaccines have proven effective against other diseases such as measles.

The Swiss National Science Foundation, which provided funding for the development of the vaccines, said in a press releaseExternal link that the vaccines are intended to be available as a nasal spray, which simplifies administration. It should also be easier to transport and store because the vaccine remains stable at higher temperatures and can therefore be used in warmer climates.

MENAFN18032022000210011054ID1103871512